GlassScriptPhysician profile
Steven Christopher Pulley
NPI 1104037878
$2,765.20
in general payments reported to CMS, 2019-2025
30 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $227 · 2021: $448 · 2022: $459 · 2023: $692 · 2024: $475 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $999.63 | 2019-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $284.99 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Abbvie INC. | $252.16 | 2021-2024 | |
| Amgen INC. | $134.21 | 2019-2024 | Krystexxa |
| Pfizer INC. | $123.06 | 2019-2021 | |
| Lundbeck LLC | $119.39 | 2022-2024 | Vyepti |
| Biodelivery Sciences International, INC. | $97.27 | 2021 | |
| Idorsia Pharmaceuticals US INC | $74.55 | 2022-2023 | Quviviq |
| Nevro Corp. | $59.76 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.50 | 2022 | |
| Allergan, INC. | $52.61 | 2020-2021 | |
| Tersera Therapeutics LLC | $51.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.12 | 2020-2025 | Relistor |
| Relievant Medsystems, INC. | $40.80 | 2021-2022 | |
| Nalu Medical, INC. | $39.55 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $39.24 | 2019-2021 | |
| Shionogi INC | $37.57 | 2019 | |
| Almatica Pharma LLC | $31.50 | 2021 | |
| Grt US Holding, INC. | $28.62 | 2020-2021 | |
| Eisai INC. | $28.59 | 2021 | |
| Virtus Pharmaceuticals LLC | $28.29 | 2021 | |
| Boston Scientific Corporation | $27.26 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $20.07 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.37 | 2021 | |
| Redhill Biopharma INC. | $14.42 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.10 | 2023 | |
| Mdd US Operations, LLC | $14.07 | 2021 | |
| Indivior INC. | $13.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.60 | 2020 | |
| Stimwave Technologies Incorporated | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pulley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.